Shots:

• The approval is based on the P-III STOP 301 trial evaluates Trudhesa (0.725 mg/spray) in 5650+ patients with migraine with or without aura for 24 or 52 wks.
• The exploratory efficacy results showed that nasal spray provides rapid- sustained- and consistent symptom relief. The therapy is well-tolerated & no serious TEAEs were observed
• Trudhesa is the first and only therapeutic to use Impel’s pod technology to deliver DHE to the vascular-rich upper nasal space. The product is expected to launch in early Oct’21 & will be available through Trudhesa Direct and the copay program

| Ref: Globe Newswire | Image: PR Newswire